Introduction
Mutations of the BRAF gene were first identified and implicated in human cancers by Davies et al in 2002 . 1 BRAF, which has been implicated in human cancer, is one of three highly conserved serine-threonine protein kinase genes (ARAF, BRAF, and CRAF) in the RAS-RAF-MEK-ERK cascade. 2 Mutations in the BRAF gene have been reported in 7%-15% of all human cancers, with melanoma having one of the highest incidences (40%-70%). 1, 2 The most common locus of mutation is at position V600, causing constitutive hyperactivation, proliferation, survival, and oncogenic transformation. 2 Other tumor types with a marked prevalence of BRAF V600 mutations include hairy cell leukemia (79%-100%), 3, 4 histiocytic conditions, including Erdheim-Chester disease and Langerhans cell histiocytosis (55%), 5 papillary thyroid carcinoma (45%), 6 serous ovarian cancer (35%), 7 colorectal cancer (12%), 1 non-small cell lung cancer (NSCLC; up to 5%), 8 and multiple myeloma (4%). 9 Oncogenic BRAF V600 mutations are often associated with an aggressive phenotype and shorter disease-free and overall survival than the wild type. 4, 6, 8, 10 correspondence: allen l cohn rocky Mountain cancer centers, 1800 Williams street, Denver, cO 80218 11 and dabrafenib 12 for the treatment of patients with metastatic melanoma have increased the interest in evaluation of these treatments in other solid tumors with BRAF mutations. Previous studies regarding the incidence of BRAF mutations in other malignancies were primarily conducted in single centers or with databases that extract mutation data from published reports. Herein, results from a large, multicenter, prospective, national screening study conducted in patients with solid tumors (other than metastatic melanoma or papillary thyroid carcinoma) and multiple myeloma are presented.
Methods

study design
Twenty oncology specialty centers (19 community centers and one academic center [Vanderbilt University]) in the US were the sites in this study. Patients $18 years of age with histologically confirmed solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma were eligible for enrollment. Patients with Eastern Cooperative Oncology Group (ECOG) performance status .2, uncontrolled concurrent malignancy, active/untreated central nervous system metastases, history of or known carcinomatous meningitis, or those who had received prior treatment with a selective BRAF or MEK inhibitor or had an uncontrolled or severe medical illness were excluded from the study. Prior treatment with sorafenib (a multitargeted tyrosine kinase inhibitor) was allowed. Formalin-fixed, paraffin-embedded tumor samples (at least five serially cut, unstained, 5-μm sections) were collected from eligible patients and sent to a central laboratory (Clarient, Inc., Aliso Viejo, CA, USA) to identify BRAF V600 mutations. Tumor samples were obtained from archival tissue (eg, from the initial diagnosis of cancer) or from fresh biopsy specimens according to institutional standards. Mutations were identified by bidirectional direct Sanger sequencing. Patient characteristics were collected, and included age, cancer diagnosis, and prior cancer treatment. All patients signed written informed consent before enrollment. This study was conducted in compliance with the International Conference on Harmonisation E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki or the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. The protocol and the study were approved by the US Oncology Inc. institutional review board and the Vanderbilt University Medical Centre institutional review board. This study was registered with ClinicalTrials.gov (ID, NCT01804140).
study objectives
The primary objective of this study was to identify patients who had solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma harboring activating BRAF V600 mutations for enrollment in a phase II clinical study (VE-BASKET; ClinicalTrials.gov ID, NCT01524978). 13 The secondary objective was to provide additional data regarding the incidence and subtype of BRAF V600 mutations in these tumor types.
Efficacy and safety outcomes
This was a screening study to identify patients with activating BRAF V600 mutations; therefore, no study treatment was administered. Consequently, there was no formal safety analysis of the study drug. Nonetheless, during the screening/study period, all adverse events (AEs) associated with the sampling or biopsy procedures were monitored and assessed to determine their relationship to study procedures for a maximum of 28 days after an intervention/invasive procedure (biopsy). During this period, any serious AE (SAE) or AE that the investigator considered as having a causal relationship to a protocol-mandated intervention/invasive procedure, regardless of the elapsed time, was reported to the sponsor. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Results
Patients
Between December 2012 and August 2013, 668 patients from 20 US-based institutions provided informed consent: 662 patients were enrolled and 548 patients were evaluable, with mutation results from sampling/biopsy procedures. One hundred fourteen patients were not evaluable because their samples were not available for testing. This includes six patients who died before sampling/biopsy procedures ( Figure S1 ).
Of the 662 patients enrolled, 100 patients (15%) had breast cancer, 100 patients (15%) had NSCLC, 84 patients (13%) had colorectal cancer, 75 patients (11%) had ovarian cancer, 23 patients (3%) had prostate cancer, 37 patients (6%) had multiple myeloma, 17 patients (3%) had a biliary tract tumor (including cholangiocarcinoma), and 226 patients (34%) had other types of solid tumors (Table S1) .
Five hundred forty-eight patients were evaluable and were enrolled in the study with mutation results from the sampling/ biopsy procedures. Characteristics of evaluable patients at enrollment are summarized in (Table 2) . No BRAF V600E mutations were identified in patients with ovarian, breast, or prostate cancer. Other subtypes investigated included V600K, V600D, V600R, and other V600 mutations. None of these other BRAF V600 mutations were identified in the screening population of the study.
Efficacy and safety
This was a screening study. No treatments were administered. Efficacy was not evaluated. No AEs or SAEs resulting from sampling were observed. The study ended early because patient recruitment to the VE-BASKET clinical trial exceeded initial expectations, 13 and it was no longer necessary to screen additional patients.
Discussion
To our knowledge, this is the first national, multicenter screening study to be conducted for BRAF V600 in multiple tumor types. Of 548 evaluable patients, 16 (3%) had tumors 
Number of previous lines of therapy, n (%) 1 131 (24) 18 (21) 22 (31) 15 (20) 7 (10) 2 (10) 5 (16) 4 (25) 58 (32) 2 154 (28) 18 (21) 27 (38) 27 (36) 13 (19) 4 (19) 10 (32) 6 (38) 49 (27) 3 89 (16) 11 (13) 12 (17) 16 (21) 13 (19) 4 (19) 3 (10) 4 (25) 26 (14) 4 55 (10) 7 (8) 5 (7) 11 (15) 8 (12) 4 (19) 2 (6) 0 18 (10) $5
102 (19) 32 (37) 5 (7) 5 (7) 27 (40) 
Notes:
a no other BRAF V600 mutations were identified; V600K, V600R, V600D, and other V600 mutations were screened for. b includes cholangiocarcinoma/cancers of the biliary tract; tumors of the gallbladder were classified as "other". Abbreviations: CI, confidence interval (based on Clopper-Pearson estimate); NSCLC, non-small cell lung cancer.
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cohn et al with a BRAF V600E mutation. No other BRAF V600 mutations were identified in this population; however, V600K, V600D, V600R, and V600E(2) have also been identified in patients with metastatic melanoma.
14 BRAF V600E mutations were distributed among a range of tumor types, including colorectal cancer (11%), biliary tract cancer (including cholangiocarcinoma, 6%), NSCLC (3%), and multiple myeloma (3%). There were no BRAF V600 mutations in patients with ovarian tumors, breast cancer, or prostate cancer.
The proportions of patients with BRAF V600 mutations identified in the screening study were similar to those seen in previously published reports, 1, [8] [9] [10] 15 with the exception of ovarian cancer. It has previously been reported that up to 14% of all ovarian cancers have activating BRAF mutations 1 [16] [17] [18] [19] [20] The finding of no mutations among 21 patients with prostate cancer is also consistent with data from the COSMIC database, showing documented BRAF mutations in ≈1% of almost 2,500 sequenced samples. Limitations of this study include having targeted only mutations at the BRAF V600 location, which might have excluded patients with mutations at other locations in exon 15 of the BRAF allele, and the lack of disease characteristics available for those patients with positive BRAF V600 mutations. Patients screened for this study and identified with BRAF V600 mutations were potentially eligible to be enrolled in the VE-BASKET study, a groundbreaking phase II study. Unlike more traditional study designs, which typically enroll patients with one type of malignancy into cohorts, "basket" design studies can be designed based on the expression of specific cellular mutations, regardless of cancer type. 13 In conclusion, the results of this screening study suggest that histology-independent trials of rare, molecularly defined populations are feasible and confirm previously reported incidences of BRAF mutations in several solid tumors and multiple myeloma, further refining the incidence for ovarian and breast cancers. 
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